Objectives. To evaluate TNF-a inhibitor (TNFi) persistence when used as first-or second-line biologic therapy for the management of PsA, and to determine baseline clinical and laboratory parameters associated with TNFi persistence.
Introduction
Psoriasis (Ps) is a common chronic inflammatory skin condition affecting 12% of the world population, and 2030% of patients with Ps have concomitant PsA [1] . Effective and tolerated early therapeutic intervention slows the progression of joint damage in PsA, and disease management approaches need therefore to employ optimal drug usage-managing disease to a relevant minimal disease activity or by a treat-to-target approach [2] , as has been the strategy in RA.
The importance of TNF-a in the pathogenesis of PsA has been demonstrated by the efficacy of TNF-a inhibitors (TNFi) [37] , which decrease joint damage both clinically and radiologically. There are currently no head-to-head trials of TNFi but indirect analyses suggest similar efficacy of different TNFi agents at 24 weeks. Notably, however, there are limited data on the success of switching to a second TNFi, when an initial TNFi has been ineffective or has caused adverse effects.
Our study objectives were to determine TNFi persistence in patients treated with their first TNFi; evaluate factors influencing TNFi persistence; and compare persistence in patients who switched to a second TNFi after failing their first TNFi.
Methods

Study population
A single-centre retrospective cohort study was performed of all PsA patients attending a secondary-care teaching hospital and commencing TNFi therapy between 2003 and 2015. Cases were classified as PsA based on either the ClAssification Criteria for Psoriatic Arthritis (CASPAR) criteria, or a rheumatologist's diagnosis of PsA. Data were collected as part of routine clinical care using electronic medical records. Having failed two or more synthetic DMARDs (sDMARD) including MTX, patients commenced either their first (first-line) or second (second-line) TNFi therapy.
Baseline characteristics
Baseline characteristics included the following: age, sex, disease duration, current disease activity [tender and swollen joint counts; patient global assessment of disease activity (PGA)], ESR, CRP, information on past and present sDMARD use, and metabolic syndrome-related co-morbidities including hypertension, diabetes and dyslipidaemia. Patients were reviewed at 3, 6, 12 and 24 months following TNFi initiation. As stipulated by the National Institute for Health and Care Excellence in the UK, the Psoriatic Arthritis Response Criteria (PsARC) was used to assess TNFi efficacy. Primary inefficacy was defined as the inability to achieve an improvement in 52/4 PsARC measures at 3 and/or 6 months [8], with no worsening in any four measures; equating to 530% improvement in tender and swollen joint scores, and 51 improvement in the patient and physician global assessment. Secondary inefficacy was defined as the loss of response in patients who had previously responded by month 6.
Statistical methods
Treatment groups (etanercept vs adalimumab users) were compared using logistic, linear or Poisson regression, as appropriate. TNFi persistence was defined as the period from drug initiation to discontinuation of TNFi or switch to another TNFi (due to inefficacy or side effects), and was evaluated using the KaplanMeier method. The log-rank test (univariable) and Cox proportional hazards models (multivariable) were used to identify factors associated with TNFi persistence. All analyses were performed using Stata 12 (StataCorp, College Station, TX, USA).
Ethical considerations
This quality improvement project was approved by the Regional Ethics Committee and Institutional Review Board. Patient consent was not required.
Results
Baseline clinical characteristics of first-line TNFi users A total of 204 biologic-naïve patients with PsA commenced TNFi therapy between 2003 and 2015. Eightysix (42%) patients were treated with adalimumab and 102 (50%) with etanercept (Table 1) . Seven patients (3%) receiving infliximab and 9 (4%) receiving golimumab were excluded due to small numbers. A total of 139/188 cases analysed (on etanercept or adalimumab) fulfilled CASPAR criteria. At baseline, the mean (S.D.) age of the first-line TNFi patients was 47.2 (11.4) years, the median (IQR) disease duration was 11 (716) years, and 46% were male. Tender and swollen joint counts, PGA and ESR did not differ between adalimumab and etanercept users, but CRP was slightly higher in the etanercept group. Fifty-six per cent of patients were current or previous smokers, and 54% had metabolic syndrome-related co-morbidities at baseline. While there was no overall difference in the presence of metabolic syndrome-related co-morbidities between the TNFi groups, there were slightly more patients with hypertension in patients receiving etanercept relative to adalimumab (48 vs 23%; P = 0.03). Concomitant sDMARD and TNFi use was significantly more common in patients using adalimumab than etanercept (75 vs 56%; P = 0.01), especially concomitant methotrexate and TNFi use (54 vs 32%; P = 0.002).
Persistence with therapy in first-line TNFi users
In first-line TNFi users, the total treatment period was 635 person-years, median duration of TNFi treatment was 26.5 months (IQR: 716 months), with no significant difference between adalimumab and etanercept users. At 3, 6, 12 and 24 months, the proportion of patients persisting with TNFi therapy was 183/188 (97%), 166/187 (89%), 133/169 (79%) and 113/155 (73%), respectively. Of the 65/188 (35%) patients discontinuing their first TNFi during the study period, 35% stopped treatment due to primary inefficacy, 21% due to secondary inefficacy and 43% due to adverse events. Adverse events included administration site reactions and skin rashes in 24% of patients; nervous system disorders in 17%; infections in 14%; paradoxical psoriasis in 14% (adalimumab only); musculoskeletal disorders in 10%; respiratory disorders in 7%; hepatobiliary disorders in 7%; and blood and lymphatic disorders in 3% of patients with PsA.
Baseline predictors of persistence with first-line TNFi therapy
Univariable analysis of first-line TNFi users demonstrated that female sex (hazards ratio (HR) = 1.84; 95% CI: 1.11, 3.04; P = 0.02), metabolic syndrome-related co-morbidities (HR = 2.39; 95% CI: 1.43, 3.98; P = 0.001), older age at PsA onset (HR = 1.03; 95% CI: 1.00, 1.05; P = 0.04) and shorter disease duration prior to TNFi initiation (HR = 0.93; 95% CI: 0.88, 0.99; P = 0.02) were associated with significantly lower TNFi persistence (Table 2 ). Multivariable analysis confirmed that female sex (HR = 2.57; 95% CI: 1.3, 5.2; P = 0.01) and any baseline metabolic syndrome-related co-morbidity (HR = 2.65; 95% CI: 1.2, 5.7; P = 0.01) were independently associated with significantly lower TNFi persistence. Parameters not statistically associated with TNFi persistence included choice of TNFi agent (adalimumab vs etanercept), concomitant sDMARD/MTX use, tender/swollen joint counts, PGA of disease activity, CRP, ESR and overall disease duration.
Persistence with TNFi therapy in second-line users A total of 32 patients had switched to using a second TNFi (59% to adalimumab, 41% to etanercept) and were analysed. The mean (S.D.) age at baseline was 50.5 (12.1) years, median (IQR) disease duration was 12 (920) years and 38% were male. A significant proportion (65%) of patients had metabolic syndrome-related co-morbidities, particularly in the adalimumab group (79% adalimumab vs 39% etanercept; P = 0.03). As for first-line TNFi users, concomitant sDMARD use was more likely with adalimumab than with etanercept (74 vs 39%; P = 0.05). Over 954 person Any metabolic/metabolic co-morbidity = hypertension, diabetes or dyslipidaemia. IRR: incidence rate ratios; PGA: physician's global assessment score. months of follow-up, the median (IQR) duration of TNFi treatment was 15.0 (552) months. At 3, 6, 12 and 24 months, the proportion of patients persisting with TNFi therapy was 29/32 (91%), 23/30 (77%), 18/27 (67%) and 15/26 (58%), respectively. Of the 18/32 (56%) discontinuing their second TNFi at the end of the study period, 77% were due to inefficacy and 22% due to adverse events.
Baseline predictors of persistence with second-line TNFi therapy
For second-line TNFi users, older age at TNFi initiation was associated with lower TNFi persistence (HR = 1.06; 95% CI: 1.0, 1.1; P = 0.02) ( Table 2) . Conversely, previous MTX use was associated with higher TNFi persistence Any metabolic/metabolic co-morbidity = hypertension, diabetes or dyslipidaemia. HR: hazard ratio; PGA: physician's global assessment score.
(HR = 0.15; 95% CI: 0.03, 0.74; P = 0.02). Due to the sample size, multivariable analyses were not permissible.
TNFi persistence in first-vs second-line TNFi users
On multivariable analysis, TNFi persistence was 2-fold less likely in second-vs first-line TNFi users (Cox proportional hazards ratio 2.02; 95% CI: 1.20, 3.42; P = 0.01), with no significant contribution from co-variables.
Discussion
Our single-centre observational study of patients with PsA found 1-year TNFi therapy persistence of 79%, which corroborates findings from European registry studies (7088%) [811] , and is higher than reported in RA registry studies [9, 10] . The proposed reasons for this difference have included improved health-related quality of life, a preferable safety profile and also the availability of biologics with alternative mechanisms of action. It will be interesting to evaluate in future studies whether biologics targeting IL-17, IL-12/23 and phosphodiesterase-4 have different persistence in PsA. They will for sure benefit patients by providing alternative therapeutic options.
In our study, first-line TNFi therapy was discontinued in 56% of cases due to inefficacy and 43% due to adverse events. These findings are as supported by registry data, with adverse events (mainly infection) accounting for 4169% of discontinuations and inefficacy accounting for 1839% [911] .
The most significant clinical factors associated with low persistence in our study were female sex and the presence of metabolic syndrome-related co-morbidities (hypertension, diabetes and/or dyslipidaemia). Female sex is a common factor associated with reduced TNFi persistence [811] and a number of studies have identified obesity as a predictor of non-responsiveness to TNFi in PsA [12, 13] , with 'any co-morbidity' correlated with failure in British Society for Rheumatology Biologics Register (BSR-BR) [11] . The underlying mechanisms that link metabolic syndrome-related co-morbidities and poor TNFi response are unclear and are likely to be multi-factorial, although adipose tissue is known to secrete pro-inflammatory cytokines such as TNF-a and IL-6 that will potentiate PsA. Previous studies have reported other baseline factors associated with lower TNFi persistence, including higher physician-reported global assessment of a disease activity [10] , higher PGA [8], higher Clinical Disease Activity Index [14] , higher HAQ [11, 14] and lower CRP [8, 15] . Interestingly we found no association between persistence and baseline CRP, ESR, tender or swollen joint counts. We demonstrated no difference in persistence between adalimumab and etanercept, which has also been the case for registry studies in PsA. In contrast, infliximab usage (a mousehuman chimeric mAb), was a significant predictor of discontinuation reported by BSR-BR [11] and Spanish Registry for Adverse Events of Biological Therapy in Rheumatic Diseases (BIOBADASER) [9] . This is likely due to increased immunogenicity as a consequence of infliximab not being fully humanized, in addition to the formation of large anti-drug antibody (ADA) immune complexes (therefore immunogenic) with infliximab, relative to adalimumab or etanercept [16] .
The benefit of concomitant methotrexate and TNFi therapy was first observed in RA, where there is evidence that methotrexate increases serum concentrations of both infliximab and adalimumab, while also decreasing ADA [16] , and there is emerging data that similar mechanisms occur in PsA [17, 18] . While concomitant methotrexate and TNFi use increased TNFi persistence in some studies in PsA [8, 15] , the Corrona registry [14] and our own results challenge those findings.
Recent clinical guidelines, for example, BSR, have not been able to categorically advocate the use of a second TNFi after inefficacy with the first TNFi, primarily due to no RCTs investigating this approach. We show 12-month persistence of 67% with second-line compared with 79% with first-line TNFi therapy. The BSR-BR [11] report 12 month persistence of 76 and 74% with first-and second-line TNFi, BIOBADASER 87 and 81% [19] , and Norwegian Anti-Rheumatic Drug Register (NOR-DMARD) (36 month persistence) of 57 and 36%, respectively [20] . Certolizumab pegol use in TNFi inadequate responders [7] found comparable ACR responses in TNFi-naïve and TNFi inadequate responders. The lower TNFi persistence observed with second-line use may be due to an increased risk of developing ADA if doing so with a first, but also drugrelated factors are important: certolizumab is probably less immunogenic due to lacking an Fc fragment coupled with the addition of the polyethylene glycol moiety [7, 16] .
Strengths of this study included unselected inclusion of all PsA cases commencing TNFi therapy in a single centre; the long duration of follow-up, starting at the introduction of TNFi therapy in this hospital; and multivariable analyses adjusting for metabolic syndrome-related comorbidities. Many registries are voluntary and require consent, thereby introducing selection bias towards a more engaged patient population, which may in turn improve persistence. Limitations of the study include the lack of adjustment for time-varying variables such as sDMARD dosing, smoking and BMI; unknown confounders such as glucocorticoid use, duration/frequency of TNFi withholding during concomitant infection/surgery which may increase ADA; and some missing data, especially for smoking and BMI.
Conclusions
TNFi remain the mainstay of management for patients with PsA who fail synthetic DMARD therapy. With the advent of therapies targeting alternative molecular pathways, the identification of patient and drug factors enabling patient stratification will become increasingly achievable. This may facilitate dose optimization; reduce immunogenicity and the development of ADA; enable selection of the appropriate molecular target; and thus increase drug persistence as the overall treatment goal.
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